请选择 进入手机版 | 继续访问电脑版
楼主: bigfoot0517
4427 6

[其他] 瑞士银行--中国中药行业研究报告2008年6月 [推广有奖]

  • 1关注
  • 21粉丝

学术权威

21%

还不是VIP/贵宾

-

威望
6
论坛币
12493617 个
通用积分
2.6112
学术水平
391 点
热心指数
369 点
信用等级
405 点
经验
28609 点
帖子
2147
精华
2
在线时间
242 小时
注册时间
2006-11-15
最后登录
2019-1-31

bigfoot0517 发表于 2008-6-25 19:11:00 |显示全部楼层 |坛友微信交流群
相似文件 换一批

+2 论坛币
k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群
赵安豆老师微信:zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

感谢您参与论坛问题回答

经管之家送您两个论坛币!

+2 论坛币
<p>Summary and investment case<br/>TCM and western medicine both have their strong points. In China it is<br/>generally believed that TCM has the advantage in the treatment of chronic and<br/>intractable diseases, such cardio-cerebral vascular diseases, strengthening the<br/>immune system and in relieving symptoms for people who feel unwell but have<br/>no identifiable disease. Western medicine is considered to be better for the<br/>treatment of medical emergencies and severe illnesses.<br/>China has historically used policy guidance to support the TCM industry. The<br/>new round of reforms to the medical system the government is currently<br/>pursuing is likely to have a direct impact on the overall pharmaceutical industry,<br/>in our view. We believe the expansion of the scope of medical insurance should<br/>increase the affordability of drugs, and the reform of medical service institutions<br/>should stimulate spending on health care services by citizens, gradually<br/>improving the environment for drug industry development. We expect TCM to<br/>play an increasingly important role in community health service centres and<br/>rural medical institutions given its perceived advantages in preventive care and<br/>health maintenance.<br/>The government is enthusiastically promoting TCM in community health<br/>service centres and rural medical institutions. However, it is important to<br/>remember that at present, most TCM products are sold in pharmacies; that is,<br/>through OTC channels. The question is whether TCM companies can take<br/>advantage of these favourable government policies. The ability of firms to<br/>develop these new markets—community health service centres and rural<br/>medical institutions—will be tested.<br/>Rising raw material prices have put margin pressure on the TCM industry, and<br/>whether or not firms have the ability to pass on increases will be key. We<br/>believe there are two main directions of development for TCM companies: (1) to<br/>leverage their brands and use pharmacy chains as their major sales channels to<br/>gradually expand into the consumer goods market and obtain greater pricing<br/>power; and (2) to rely on technological and technical advantages, using hospitals<br/>as their main sales channels and modern TCM products as the direction of<br/>development, to maintain high profit margins by continuously launching new<br/>products and new formats.<br/>In the long term we see two major investment themes for the TCM industry: (1)<br/>against a background of rising ingredient prices, companies that have the ability<br/>to raise prices; and (2) against a background of medical reform, companies that<br/>stand to benefit from that reform.<br/>We believe that among TCM companies holding traditional brands, Shandong<br/>Dong-e E-jiao (DEEJ) and Yunnan Baiyao (YB) have relatively strong pricesetting<br/>ability, which is based on good marketing ability and brand management.<br/>Guangzhou Pharmaceutical’s (GZP) herbal tea operations also have relatively<br/>strong price-setting capacity, in our view.</p><p>Among modern TCM firms, Tianjin Tasly Pharmaceutical (Tasly), which uses<br/>hospitals as one of its main sales channels, is currently focusing on developing<br/>in the community health service centre and rural medical institution markets.<br/>This kind of firm is more likely to be able to profit from the trend for increased<br/>drug usage at basic medical service institutions brought about by medical reform.<br/>However, since we anticipate a lag before TCM companies benefit from medical<br/>reform, we believe it will be important to follow developments in this area.</p><p>Contents page<br/>Summary and investment case 3<br/>Industry analysis 8<br/>Industry risks 22<br/>Valuation and comparables 24<br/>Company pages 33<br/>— Shandong Dong-E E-Jiao.....................................................................................34<br/>— Investment case .............................................................................................35<br/>— Company risks ...............................................................................................42<br/>— Financials .......................................................................................................43<br/>— Price target derivation ....................................................................................47<br/>— Company background ....................................................................................48<br/>— Guangzhou Pharmaceutical .................................................................................51<br/>— Investment case .............................................................................................52<br/>— Company risks ...............................................................................................59<br/>— Financials .......................................................................................................60<br/>— Price target derivation ....................................................................................65<br/>— Company background ....................................................................................66<br/>— Guangzhou Pharmaceutical - A ...........................................................................69<br/>— Investment case .............................................................................................70<br/>— Company risks ...............................................................................................77<br/>— Financials .......................................................................................................78<br/>— Price target derivation ....................................................................................83<br/>— Company background ....................................................................................84<br/>— Tianjin Tasly Pharmaceuticals (G) .......................................................................87<br/>— Beijing Tongrentang (G) .......................................................................................94<br/>— Tong Ren Tang Technologies ............................................................................100<br/>— Yunnan Baiyao Group (G) ..................................................................................106</p><p></p><p> 222668.pdf (1.03 MB, 需要: 10 个论坛币) <br/></p><p></p>
二维码

扫码加我 拉你入群

请注明:姓名-公司-职位

以便审核进群资格,未注明则拒绝

关键词:行业研究报告 中药行业 研究报告 瑞士银行 行业研究 investment advantage 瑞士银行 medicine 研究报告

已有 1 人评分学术水平 收起 理由
emaivy + 1 奖励积极上传好的资料

总评分: 学术水平 + 1   查看全部评分

 A good template for analysis document.

使用道具

小小生 发表于 2008-6-29 11:50:00 |显示全部楼层 |坛友微信交流群
还贵  但是还是买了 是个好模板

使用道具

qingcha0077 发表于 2010-3-24 23:28:46 |显示全部楼层 |坛友微信交流群
还贵  但是还是买了 是个好模板
本文来自: 人大经济论坛 详细出处参考:http://www.pinggu.org/bbs/viewth ... &from^^uid=667558
需要论坛币买贵书,不得已卖点贵书.论坛上传总有问题 有打不开站内联系

使用道具

lingyuncpu 发表于 2010-9-29 16:58:31 |显示全部楼层 |坛友微信交流群
有没有中文的

使用道具

llsuperman 在职认证  发表于 2010-11-10 03:46:21 |显示全部楼层 |坛友微信交流群
顶起 好货。。。。。

使用道具

emaivy 发表于 2012-7-20 12:53:06 |显示全部楼层 |坛友微信交流群
lz ,便宜点吧

使用道具

您需要登录后才可以回帖 登录 | 我要注册

本版微信群
加JingGuanBbs
拉您进交流群

京ICP备16021002-2号 京B2-20170662号 京公网安备 11010802022788号 论坛法律顾问:王进律师 知识产权保护声明   免责及隐私声明

GMT+8, 2024-3-29 01:36